BELLEVUE GROUP AG
Q3 2026 Form 13-F

KUESNACHT
CIK 0001674546 · Institutional investment manager
Consolidated report · includes 2 managers since Q1 2020
$4.8B Reported Value Total
Reported value
$4.8B
Quarter over quarter
+2.0%
Holdings
154
Top-10 concentration
47.1%

Filing Structure

Reports holdings for

  • Bellevue Asset Management UK Ltd · File #028-20408 · Q1 2024 – Q4 2025
  • BB Biotech AG (not a 13F filer in our records) · File #28-06964 · Q2 2019 – Q3 2024 · declared by one filing
  • Bellevue Asset Management AG (not a 13F filer in our records) · File #28-16892 · Q1 2016 – Q3 2024 · declared by one filing
  • Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · File #28-20408 · Q4 2020 – Q3 2024 · declared by one filing
  • Bellevue Asset Management (UK) Ltd. (not a 13F filer in our records) · Q3 2020 – Q3 2020 · declared by one filing
  • Biotech Target N V (not a 13F filer in our records) · File #28-11189 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Invest N V (not a 13F filer in our records) · File #28-11191 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Focus N V (not a 13F filer in our records) · File #28-11193 · Q2 2019 – Q2 2019 · declared by one filing
  • Biotech Growth N V (not a 13F filer in our records) · File #28-11194 · Q2 2019 – Q2 2019 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Christoph Eisenring / Stefano Montalbano
Head Legal & Compliance / CFO

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $4.8B
Positions 154
Change in reported value +1.4%
New positions 25
Exited positions 19
Position turnover 25.4%
Top-10 concentration 47.1%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
154 $4.8B
Q2 2026 13F
Filed Aug 14, 2026
148 $4.8B
Q1 2026 13F
Filed May 15, 2026
155 $4.2B
Q4 2025 13F
Filed Feb 17, 2026
176 $5.3B
Q3 2025 13F
Filed Nov 14, 2025
148 $4.8B
Q2 2025 13F
Filed Aug 14, 2025
142 $4.5B
Q1 2025 13F
Filed May 14, 2025
148 $4.5B
Q4 2024 13F
Filed Feb 14, 2025
160 $5.2B
Q3 2024 13F
Filed Nov 14, 2024
162 $6.2B
Q2 2024 13F
Filed Aug 14, 2024
166 $6.2B
Q1 2024 13F
Filed May 15, 2024
169 $6.6B
Q4 2023 13F
Filed Feb 14, 2024
161 $6.5B
Q3 2023 13F
Filed Nov 14, 2023
154 $6.2B
Q2 2023 13F
Filed Aug 14, 2023
156 $7.0B
Q1 2023 13F
Filed May 15, 2023
159 $6.9B
Q4 2022 13F
Filed Feb 14, 2023
171 $7.5B
Q3 2022 13F
Filed Nov 14, 2022
176 $7.0B
Q2 2022 13F
Filed Aug 11, 2022
172 $7.1B
Q1 2022 13F
Filed May 13, 2022
177 $8.6B
Q4 2021 13F
Filed Feb 10, 2022
191 $9.7B

23 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 AMGN AMGEN INC $363.2M 7.54%
2 GILD GILEAD SCIENCES INC $320.6M 6.65%
3 VRTX VERTEX PHARMACEUTICALS INC $302.5M 6.28%
4 ARGX ARGENX SE $278.6M 5.78%
5 REGN REGENERON PHARMACEUTICALS $212.0M 4.4%
6 RVMD REVOLUTION MEDICINES INC $205.0M 4.25%
7 INSM INSMED INC $172.1M 3.57%
8 VRDN VIRIDIAN THERAPEUTICS INC $146.4M 3.04%
9 ORKA ORUKA THERAPEUTICS INC $136.7M 2.84%
10 BIIB BIOGEN INC $135.1M 2.8%
11 SRRK SCHOLAR ROCK HLDG CORP $134.7M 2.79%
12 PCVX VAXCYTE INC $132.1M 2.74%
13 RLAY RELAY THERAPEUTICS INC $111.7M 2.32%
14 ABT ABBOTT LABORATORIES $103.6M 2.15%
15 UTHR UNITED THERAPEUTICS CORP DEL $101.0M 2.1%
16 ISRG INTUITIVE SURGICAL INC $100.8M 2.09%
17 MDT MEDTRONIC PLC $90.0M 1.87%
18 BBIO BRIDGEBIO PHARMA INC $78.7M 1.63%
19 IMCR IMMUNOCORE HLDGS PLC $68.6M 1.42%
20 ELVN ENLIVEN THERAPEUTICS INC $67.3M 1.4%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings